0.78 0.01 (1.3%) | 06-28 15:48 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 0.7 | 1-year : | 0.85 |
Resists | First : | 0.6 | Second : | 0.73 |
Pivot price | 0.52 | |||
Supports | First : | 0.39 | Second : | 0.32 |
MAs | MA(5) : | 0.53 | MA(20) : | 0.55 |
MA(100) : | 0.79 | MA(250) : | 0.73 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 44.6 | D(3) : | 46.8 |
RSI | RSI(14): 45 | |||
52-week | High : | 1.39 | Low : | 0.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ERYP ] has closed below upper band by 40.7%. Bollinger Bands are 31.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.54 - 0.54 | 0.54 - 0.55 |
Low: | 0.48 - 0.48 | 0.48 - 0.48 |
Close: | 0.53 - 0.54 | 0.54 - 0.54 |
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
Mon, 08 May 2023
ERYTECH Provides Business and Financial Update for the First Quarter of 2023 - Yahoo Finance
Wed, 15 Feb 2023
ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended ... - GlobeNewswire
Mon, 25 Apr 2022
ERYTECH Sells U.S. Manufacturing Facility and Enters - GlobeNewswire
Wed, 01 Dec 2021
Company News for Dec 1, 2021 - Yahoo Movies Canada
Tue, 16 Nov 2021
Our First Look At ERYTECH Pharma Stock (NASDAQ:ERYP) - Seeking Alpha
Tue, 09 Nov 2021
ERYTECH to Present at the 12th Annual Jefferies Global London Healthcare Conference - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 0 (M) |
Held by Insiders | 0 (%) |
Held by Institutions | 0 (%) |
Shares Short | 0 (K) |
Shares Short P.Month | 0 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | 0 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0.1 |
EBITDA (p.s.) | -0.42 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 4.92 |
Price to Cash Flow | 0 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |